Literature DB >> 31996445

Correlation between Broth Microdilution and Disk Diffusion Results when Testing Ceftazidime-Avibactam against a Challenge Collection of Enterobacterales Isolates: Results from a Multilaboratory Study.

Helio S Sader1, Paul R Rhomberg2, Sukantha Chandrasekaran3, Marisol Trejo3, Kelley A Fedler2, Linda D Boyken4, Daniel J Diekema4.   

Abstract

We assessed the ceftazidime-avibactam disk diffusion breakpoints that provide the lowest discrepancy error rates by testing an Enterobacterales isolate collection with ceftazidime-avibactam MIC values near the breakpoints. Isolates (n = 112) were susceptibility tested by broth microdilution and disk diffusion methods in 3 laboratories. Current disk diffusion breakpoints (≥21/≤20 mm for susceptible/resistant) provided the lowest error rates, but confirmatory MIC testing is indicated for isolates with inhibition zones of 20 to 22 mm.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  CRE; Enterobacteriaceaezzm321990; KPC; ceftazidime-avibactam; disk diffusion

Mesh：

Substances：

Year:  2020        PMID： 31996445      PMCID： PMC7098758          DOI： 10.1128/JCM.01757-19

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  17 in total

1.  Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo.

Authors:  Stephan Göttig; Denia Frank; Eleonora Mungo; Anika Nolte; Michael Hogardt; Silke Besier; Thomas A Wichelhaus
Journal:  J Antimicrob Chemother       Date:  2019-11-01       Impact factor: 5.790

2.  Emerging Resistance, New Antimicrobial Agents  …  but No Tests! The Challenge of Antimicrobial Susceptibility Testing in the Current US Regulatory Landscape.

Authors:  R M Humphries; J A Hindler
Journal:  Clin Infect Dis       Date:  2016-03-29       Impact factor: 9.079

Review 3.  The global epidemiology of carbapenemase-producing Enterobacteriaceae.

Authors:  David van Duin; Yohei Doi
Journal:  Virulence       Date:  2016-08-11       Impact factor: 5.882

4.  Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016.

Authors:  Helio S Sader; Mariana Castanheira; Dee Shortridge; Rodrigo E Mendes; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

Review 5.  The Epidemiology, Evolution, and Treatment of KPC-Producing Organisms.

Authors:  Ann Marie Porreca; Kaede V Sullivan; Jason C Gallagher
Journal:  Curr Infect Dis Rep       Date:  2018-05-05       Impact factor: 3.725

6.  Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2.

Authors:  Peera Hemarajata; Romney M Humphries
Journal:  J Antimicrob Chemother       Date:  2019-05-01       Impact factor: 5.790

7.  Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  Ryan K Shields; Cornelius J Clancy; A William Pasculle; Ellen G Press; Ghady Haidar; Binghua Hao; Liang Chen; Barry N Kreiswirth; M Hong Nguyen
Journal:  J Clin Microbiol       Date:  2018-01-24       Impact factor: 5.948

8.  Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.

Authors:  Mical Paul; George L Daikos; Emanuele Durante-Mangoni; Dafna Yahav; Yehuda Carmeli; Yael Dishon Benattar; Anna Skiada; Roberto Andini; Noa Eliakim-Raz; Amir Nutman; Oren Zusman; Anastasia Antoniadou; Pia Clara Pafundi; Amos Adler; Yaakov Dickstein; Ioannis Pavleas; Rosa Zampino; Vered Daitch; Roni Bitterman; Hiba Zayyad; Fidi Koppel; Inbar Levi; Tanya Babich; Lena E Friberg; Johan W Mouton; Ursula Theuretzbacher; Leonard Leibovici
Journal:  Lancet Infect Dis       Date:  2018-02-16       Impact factor: 25.071

Review 9.  Optimizing therapy in carbapenem-resistant Enterobacteriaceae infections.

Authors:  Mario Tumbarello; Angela Raffaella Losito; Helen Giamarellou
Journal:  Curr Opin Infect Dis       Date:  2018-12       Impact factor: 4.915

10.  Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.

Authors:  David van Duin; Judith J Lok; Michelle Earley; Eric Cober; Sandra S Richter; Federico Perez; Robert A Salata; Robert C Kalayjian; Richard R Watkins; Yohei Doi; Keith S Kaye; Vance G Fowler; David L Paterson; Robert A Bonomo; Scott Evans
Journal:  Clin Infect Dis       Date:  2018-01-06       Impact factor: 9.079
View more
  4 in total

1.  Imipenem-Relebactam Susceptibility Testing of Gram-Negative Bacilli by Agar Dilution, Disk Diffusion, and Gradient Strip Methods Compared with Broth Microdilution.

Authors:  Hanna Hakvoort; Evelyn Bovenkamp; Kerryl E Greenwood-Quaintance; Suzannah M Schmidt-Malan; Jay N Mandrekar; Audrey N Schuetz; Robin Patel
Journal:  J Clin Microbiol       Date:  2020-09-22       Impact factor: 5.948

2.  Evaluation of the Etest and disk diffusion method for detection of the activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa in China.

Authors:  Qi Wang; Feifei Zhang; Zhanwei Wang; Hongbin Chen; Xiaojuan Wang; Yawei Zhang; Shuguang Li; Hui Wang
Journal:  BMC Microbiol       Date:  2020-06-29       Impact factor: 3.605

3.  Assessment of Ceftazidime-Avibactam 30/20-μg Disk, Etest versus Broth Microdilution Results When Tested against Enterobacterales Clinical Isolates.

Authors:  Renru Han; Xuelin Yang; Yang Yang; Yan Guo; Dandan Yin; Li Ding; Shi Wu; Demei Zhu; Fupin Hu
Journal:  Microbiol Spectr       Date:  2022-01-12

4.  The Potential Use of Ceftazidime-Avibactam Against Carbapenem Resistant Klebsiella pneumoniae Clinical Isolates Harboring Different Carbapenemase Types in a Thai University Hospital.

Authors:  Worapong Nasomsong; Parnrada Nulsopapon; Dhitiwat Changpradub; Manat Pongchaidecha; Supanun Pungcharoenkijkul; Piraporn Juntanawiwat; Waristha Simsiriporn; Wichai Santimaleeworagun
Journal:  Drug Des Devel Ther       Date:  2021-07-16       Impact factor: 4.162
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.